Cypress Returns Fire Against Glaxo Over Zantac

Law360 (July 18, 2007, 12:00 AM EDT) -- A generic drug maker has opposed Glaxo Group Ltd.'s patent claims over ulcer drug Zantac, claiming that the patent is invalid and noninfringed.

Cypress Pharmaceutical Inc. filed counterclaims against Glaxo in the U.S. District Court for the Southern District of New York on Tuesday, saying that its Abbreviated New Drug Application for a generic Zantac syrup does not infringe any valid claims for Glaxo's patent, U.S. Patent Number 5,068,249.

“Cypress' commercial manufacture, use, sale or offer to sell Cypress' product for which it seeks FDA approval...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.